文献速递儿科与产科急症心脑血管急症

左乙拉西坦与苯妥英作为儿童惊厥性癫痫持续状态二线治疗的比较(ConSEPT):一项开放标签、多中心、随机对照试验

Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.
PubMed 文献 · Lancet · 2019-04-17
一句话结论在儿童惊厥性癫痫持续状态二线治疗中,左乙拉西坦并不优于苯妥英:给药后5分钟惊厥停止率苯妥英组60% vs 左乙拉西坦组50%,差异未达统计学显著。

ConSEPT是一项在澳大利亚和新西兰13个急诊科开展的开放标签、多中心、随机对照试验,纳入3个月至16岁、一线苯二氮䓬治疗失败的惊厥性癫痫持续状态患儿,按1:1随机接受20 mg/kg苯妥英(静脉或骨内输注20分钟)或40 mg/kg左乙拉西坦(静脉或骨内输注5分钟)。主要终点为研究药物输注完成后5分钟惊厥临床停止,意向治疗分析显示苯妥英组68例(60%)、左乙拉西坦组60例(50%)达到主要终点(风险差-9.2%[95%CI -21.9至3.5];p=0.16)。苯妥英组1例在27天时死于出血性脑炎,认为与研究药物无关,无其他严重不良事件。作者结论为左乙拉西坦在儿童惊厥性癫痫持续状态二线治疗中不优于苯妥英。

要点

  • 主要终点(输注完成后5分钟惊厥临床停止)苯妥英组68例(60%)vs 左乙拉西坦组60例(50%),风险差-9.2%(95%CI -21.9至3.5),p=0.16,未达统计学显著。
  • 给药方案:苯妥英20 mg/kg静脉或骨内输注20分钟;左乙拉西坦40 mg/kg静脉或骨内输注5分钟。
  • 适用人群为3个月至16岁、一线苯二氮䓬治疗失败的惊厥性癫痫持续状态患儿,研究在13个急诊科开展。
  • 苯妥英组1例在27天时死于出血性脑炎,认为与研究药物无关;无其他严重不良事件。
  • 作者结论:左乙拉西坦在儿童惊厥性癫痫持续状态二线治疗中不优于苯妥英。

适用人群与场景

  • 3个月至16岁、惊厥性癫痫持续状态且一线苯二氮䓬治疗失败的儿童,就诊于澳大利亚和新西兰13个急诊科。

处置流程与药物剂量

  • 苯妥英20 mg/kg,静脉或骨内输注,输注时间20分钟。
  • 左乙拉西坦40 mg/kg,静脉或骨内输注,输注时间5分钟。

研究设计与关键结果

  • ConSEPT为开放标签、多中心、随机对照试验,在澳大利亚和新西兰13个急诊科开展;2015年3月19日至2017年11月29日期间,639名儿童因惊厥性癫痫持续状态就诊,127名被遗漏,278名不符合入选标准,1名家长拒绝知情同意,最终233名儿童纳入意向治疗分析(苯妥英组114例,左乙拉西坦组119例)。
  • 主要终点为研究药物输注完成后5分钟惊厥临床停止,苯妥英组68例(60%)vs 左乙拉西坦组60例(50%),风险差-9.2%(95%CI -21.9至3.5),p=0.16。
  • 苯妥英组1例在27天时死于出血性脑炎,认为与研究药物无关;无其他严重不良事件。

证据类型、等级与局限

  • 证据类型:开放标签、多中心、随机对照试验(ConSEPT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:左乙拉西坦在儿童惊厥性癫痫持续状态二线治疗中不优于苯妥英。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Phenytoin is the current standard of care for second-line treatment of paediatric convulsive status epilepticus after failure of first-line benzodiazepines, but is only effective in 60% of cases and is associated with considerable adverse effects. A newer anticonvulsant, levetiracetam, can be given more quickly, is potentially more efficacious, and has a more tolerable adverse effect profile. We aimed to determine whether phenytoin or levetiracetam is the superior second-line treatment for paediatric convulsive status epilepticus.

METHODS: ConSEPT was an open-label, multicentre, randomised controlled trial conducted in 13 emergency departments in Australia and New Zealand. Children aged between 3 months and 16 years, with convulsive status epilepticus that failed first-line benzodiazepine treatment, were randomly assigned (1:1) using a computer-generated permuted block (block sizes 2 and 4) randomisation sequence, stratified by site and age (≤5 years, >5 years), to receive 20 mg/kg phenytoin (intravenous or intraosseous infusion over 20 min) or 40 mg/kg levetiracetam (intravenous or intraosseous infusion over 5 min). The primary outcome was clinical cessation of seizure activity 5 min after the completion of infusion of the study drug. Analysis was by intention to treat. This trial is registered with the Australian and New Zealand Clinical Trials Registry, number ACTRN12615000129583.

FINDINGS: Between March 19, 2015, and Nov 29, 2017, 639 children presented to participating emergency departments with convulsive status epilepticus; 127 were missed, and 278 did not meet eligibility criteria. The parents of one child declined to give consent, leaving 233 children (114 assigned to phenytoin and 119 assigned to levetiracetam) in the intention-to-treat population. Clinical cessation of seizure activity 5 min after completion of infusion of study drug occurred in 68 (60%) patients in the phenytoin group and 60 (50%) patients in the levetiracetam group (risk difference -9·2% [95% CI -21·9 to 3·5]; p=0·16). One participant in the phenytoin group died at 27 days because of haemorrhagic encephalitis; this death was not thought to be due to the study drug. There were no other serious adverse events.

INTERPRETATION: Levetiracetam is not superior to phenytoin for second-line management of paediatric convulsive status epilepticus.

FUNDING: Health Research Council of New Zealand, A+ Trust, Emergency Medicine Foundation, Townsville Hospital Private Practice Fund, Eric Ormond Baker Charitable Fund, and Princess Margaret Hospital Foundation.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet. 2019. PMID: 31005386. doi:10.1016/S0140-6736(19)30722-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。